FUEL
2020
Fontan Udenafil Exercise Longitudinal Trial
In 400 adolescents with Fontan circulation, udenafil did not significantly improve peak oxygen consumption compared with placebo, although exercise performance at the ventilatory anaerobic threshold improved.
Result
- Absolute difference
- 3.0 points
The absolute difference is derived from the event rates.
Also reported: Primary endpoint missed. At the ventilatory anaerobic threshold, VO₂ (p=0.012), ventilatory efficiency (p=0.014) and work rate (p=0.021) all improved.
- Subtopic
- Fontan circulation
- Design
- Phase-3, double-blind, placebo-controlled RCT over 26 weeks
- Relevance
- Supporting: context rather than must-know.
- Cited in
- ACC/AHA 2025 ACHD
- Source
- Goldberg DJ, Zak V, Goldstein BH, et al. Circulation. 2020;141(8):641-651.doi 10.1161/CIRCULATIONAHA.119.044352
Discussion & critique
The primary endpoint was formally missed and the submaximal gains are of uncertain clinical relevance, in a young and unusually well cohort. It is by far the largest randomised pharmacotherapy trial ever conducted in Fontan physiology and is why PDE5 inhibition remains an option rather than standard care.